Objectives: This study sought to validate the V-RESOLVE score system.
inappropriate, the prevalent strategy of stenting in main vessel (MV) and provisionally stenting in SB leads to an SB occlusion rate of 6.1%-18% as previously reported [3] [4] [5] [6] [7] [8] , which suggests us that some bifurcation lesions are vulnerable to SB occlusion if treated with the provisional strategy. Identifying angiographic characteristics related with SB occlusion can help decision-making in interventional strategy.
The Visual estimation for Risk prEdiction of Side branch OccLusion in coronary bifurcation intervention (V-RESOLVE) score was developed by Dou et al. to predict the risk of SB occlusion after MV stenting in coronary bifurcation lesions [9] . The score system comprises six independent visually estimated risk predictors for SB occlusion, including four preprocedural angiographic predictors (plaque distribution at the bifurcation, diameter stenosis of bifurcation core, bifurcation angle, and diameter ratio between MV/SB) and two predictors after predilation of MV and before MV stents implantation (MV TIMI flow grade and diameter stenosis of SB before MV stenting). The risk of SB occlusion was predicted according to total points scored with respect to different levels of the six predictors, ranging from 0 to 43. Furthermore, the V-RESOLVE score stratifies patients who score 0-11 as nonhigh risk of SB occlusion and the others scoring more than 11 as high risk of SB occlusion.
However, the derived V-RESOLVE score system is required for validation of its effectiveness and clinical usefulness. This study aims to validate the V-RESOLVE score system in another cohort of patients who underwent bifurcation intervention subsequent to the derivation cohort in our center.
| M A TE RI A L S A ND M E TH ODS

| Population and data collection
We retrospectively reviewed the coronary angiographic data of 7, 977 consecutive patients receiving elective PCI at Fuwai Hospital in Beijing, China from January 2013 to June 2013 ( Figure 1 ). Patients with coronary bifurcation lesions undergoing elective PCI with provisional strategy were included. Exclusion criteria were (1) patients who underwent intervention without ostium of the SB involved; (2) patients who diagnosed with acute myocardial infarction and received primary PCI; (3) patients with bifurcation lesions and electively stenting in the SB before the MV stenting; and (4) patients with a chronic total occlusion (CTO) lesion and SB appeared in the dismal segment after the occluded lesion opened. Clinical data were collected and reviewed through electronic medical records, and angiographic and procedural data (Supporting Information, Table 1) were obtained under the approval of the core laboratory of Fuwai Hospital. PCI procedure and peri-procedural medications followed the operators' discretion and updated guidelines at the time (Supporting Information).
| Visual estimation and V-RESOLVE score calculation
The visual estimation was performed for the coronary angiograms of the enrolled bifurcation lesions at baseline and after predilation by an independent, experienced observer in the core laboratory of Fuwai Hospital, who was not involved in the development study. The results of SB after MV stenting were concealed from the observer and then the angiographic data including the V-RESOLVE score predictors were visually estimated. Specifically, the ratio between MV/SB was calculated after visually estimating the reference diameter of MV and SB, and the rest of the five predictors were directly visually assessed. With the visual estimation results of the predictors, we calculated the V-RESOLVE score points, which referred to the derived scoring approach of the V-RESOLE score (Supporting Information, Table 2 ).
| Definitions
A coronary bifurcation lesion was defined as a coronary artery narrowing occurring adjacent to or involving the origin of a significant SB undergoing PCI. The significant SB was defined with reference to European Bifurcation Club [10] . Empirically, a significant SB was of reference diameter with 1.5 mm or more, and other factors including coronary anatomic variation, collateralizing vessel, dominated area of myocardium, and clinical symptom of patients were also taken into consideration. The bifurcation core was defined as the 5-mm part of the main vessel before the carina, and SB occlusion after MV stenting was defined as any decrease in TIMI flow grade or the absence of flow in the SB after the stent(s) was (were) deployed across the bifurcation segment in the MV. The statistical performance of the prediction model consisted of discrimination, calibration, and clinical usefulness. Discrimination was assessed by the C-statistic which is identical to the area under the receiver operating characteristic (ROC) curve [11] . Comparison of the C-statistics was performed by comparing areas under the ROC curves with Delong's method [12] . Calibration was evaluated using calibration plots with detailed assessments (Supporting Information) [13] [14] [15] [16] . The first calibration step was to compare the mean predicted probability and the mean observed frequency of SB occlusion with calibration-in-the-large, which ideally values zero. The second calibration step was to compare the overall predictive effect with the graphical assessment of the calibration plot and the estimation of the calibration slope, which, if different from 1, reflects differences from the original model. The last calibration step was to re-estimate the predictor effects in the validation cohort and calculate the differences in the effect of each predictor between the validation data and the original model. To evaluate the clinical usefulness, we first used the maximum of the Youden index to determine the diagnostic cutoff value of the V-RESOLVE score for SB occlusion in the validation cohort and then tested whether it was identical or close to the derived cutoff [17] . The sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), and accuracy were estimated to evaluate the potential clinical usefulness of the risk stratification determined by the V-RESOLVE score [18] .
| Statistical methods
All P values were two-tailed, and a P value of <0.05 was considered statistically significant. All analyses were performed using SPSS Abbreviations: CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention. Continuous are presented as the mean 6 standard deviation or median (interquartile range) as appropriate; nominal data are presented as % (n/N).
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The value of calibration-in-the-large was 20.03 (95% CI: 20.18-0.12, P 5 0.73), suggesting agreement between mean predicted probability by the V-RESOLVE score and mean observed frequency of SB occlusion in the validation cohort. The calibration slope was slightly larger than 1 (1.25, 95% CI: 1.08-1.41, P < 0.01), suggesting stronger overall predictive effects. Graphic examination of the calibration plots detected overestimation among low predicted probabilities and a trend of underestimation as the predicted probability increased (Figure 3 ).
Specifically, the predictive effect of the diameter stenosis of the SB before MV stenting was stronger (P < 0.01) in the validation cohort.
Details of the re-estimated predictor effects and differences from the original model are shown in Supporting Information, Tables 3 and 4 .
The predicted risks of SB occlusion associated with each point of the V-RESOLVE score (0-43) according to the validation and derivation cohorts are presented in Table 3 . Score points of lesions in the validation cohort ranged from 0 to 27.
According to our previous study, we stratified lesions with V-RESOLVE score points at 12 or more to the high-risk group and points at 11 or less, to the non-high-risk group. The Youden index maximized at the point of 12, suggesting the optimal diagnostic cutoff of SB occlusion in the validation cohort. The non-high-risk group comprised 61.59% of all the lesions in the validation cohort, while the high-risk Table 4 illustrates the potential clinical usefulness of the risk stratification based on the V-RESOLVE score in the validation and the derivation cohorts. Sensitivity and PPV of the stratification were greater in the validation cohort, while the derivation cohort suggested higher specificity and accuracy by using the stratification. The NPV was comparable in the two cohorts and notably higher than 95%.
| D I SCUSSION
The major findings of this study are as follows: The V-RESOLVE score system provided good discrimination and overall accurate prediction of pretest probability in the temporal validation cohort of patients undergoing coronary bifurcation interventions with provisional strategy. The combined predictive effect of the V-RESOLVE score for the validation cohort was slightly larger than that for the original model, mainly due to the enhanced effect of the diameter stenosis of the SB before MV stenting. The risk stratification based on V-RESOLVE score reevaluated by the validation cohort suggested usefulness for treatment strategy decision-making.
Previous studies have reported predictors of SB occlusion after MV stenting in coronary bifurcation lesions such as true bifurcation lesion, small SB reference, MV plaque thickness, and preprocedural stenosis of the SB 50% [4, 7, 19, 20] . However, the reported predictors were concluded from analyses by quantitative coronary angiography, optical coherence tomography (OCT), or intravascular ultrasound rather than directly visual estimation. The V-RESOLVE score system can predict the risk of SB occlusion and provide a risk stratification reference with real-time visual estimation on related angiographic predictors and user-friendly score calculations. Therefore, operators could use the score system to make treatment decisions according to angiographic results during coronary bifurcation interventions.
This study enrolled patients with bifurcation lesions treated in a year later than those in the derivation cohort. Noticeably, the complexity of the included bifurcation lesions for validation was greater on average, as suggested by the lesion characteristics and corresponding predictors in the V-RESOLVE score system. We attributed these changes mainly to the improvement of experience and technique in the coronary intervention of the operators and the fast development of the hierarchical diagnosis and treatment system in China, which resulted in the increased admission and treatment of patients with complex coronary lesions in our center. Therefore, it is reasonable that compared with the derivation cohort, the mean V-RESOLVE score points of the lesions of the validation cohort was higher and the incidence of SB occlusion. To our knowledge, it is those visually complex bifurcation lesions that are prone to confuse the choice of interventional strategy and, from this perspective, this study might provide important implications to contemporary treatment of coronary bifurcation lesions.
When calibrating the V-RESOLVE score system, we detected that the predicted result tended to underestimate the observed SB occlusion incidence especially in the range of high score points, which was mainly attributable to the strengthened effect of the predictor of the diameter stenosis of the SB before MV stenting. Potential reasons might lie in the differences in the bifurcation lesion characteristics between the two cohorts. According to the OCT analysis by Kini et al. [20] , bifurcation lesions with SB ostium diameter stenosis >50% were characterized with more frequency of lipid-rich plaque, more lipid arc, and higher lipid volume index in MV. These characteristics suggested poor fixity of plaque in MV, which led to more likelihood of plaque shift at the bifurcation during MV stenting that compromises the SB ostium and impairs the flow [21, 22] . The validation cohort had much higher proportion of bifurcation lesions with 50% or greater SB diameter stenosis than the derivation cohort (33.1% vs 6.7%, P < 0.001 for comparison). We considered that the diameter stenosis of the SB before MV stenting was associated with the status of MV plaque, and therefore, its predictive effect for SB occlusion enhanced in the validation cohort potentially attributed to more frequent SB occlusion caused by the shift of lipid-rich MV plaques during intervention. However, the Sensitivity and specificity of the risk stratification based on the V-RESOLVE score were satisfactory. The accuracy was lower in the validation cohort but also reached near 70%. As patients without SB occlusion accounted for the majority, the accuracy decreased mainly due to the lower ratio of true negative rate in the validation cohort, in accord with the decreased specificity. Meanwhile, the PPV of the risk stratification, which was associated with the incidence rate of SB occlusion, was relatively low in both the validation and the derivation cohort.
However, the risk stratification indicated excellent NPV, which was higher than 95%, meaning that there is more than 95% probability that the SB will not occlude, if the bifurcation lesion is stratified as nonhigh risk. Accordingly, patients with non-high-risk bifurcation lesions categorized by the V-RESOLVE score can be quite safe from SB occlusion following one-stent technique intervention. In our previous and current study, the non-high-risk bifurcation lesions accounted for 60%-75%
of all lesions; thus, precise identification this subgroup of patients, for whom the provisional strategy will be both safe and effective, is not only of therapeutic significance but also of hygienic economic values.
The strength of our study is that we validated the V-RESOLVE score system in an independent cohort selected from consecutive patients undergoing bifurcation intervention and evaluated the performance of the V-RESOLVE score system to predict the risk of SB occlusion and its clinical utility for risk stratification. The acceptable discrimination and calibration of the score system validated the performance of the V-RESOLVE score in patients with different lesion characteristics. Furthermore, we found that the risk stratification by V-RESOLVE score could accurately distinguish patients with different risk profiles, especially low-risk patients. Therefore, our validation study provides evidence of the utility of V-RESOLVE score in the clinical practice and implications for future research on the intervention of coronary bifurcation lesions.
This study has several limitations. First, the visual estimation for angiographic data was conducted by only one independent observer, who was not involved in our previous study. As high variability in the visual estimation of coronary angiograms among interventional cardiologists have been reported [23] , whether the inevitable intra-and interobserver variation in visual estimation will weaken the predictive accuracy of V-RESOLVE score needs further evaluation on the testretest agreement of the observer and the reliability of operators with different treatment experience. Second, this study was retrospective, and patients were enrolled from a single center, which might introduce confounders and selection bias. Third, this study was a temporal validation study conducted in the same center as the development study, of which the results should be considered less powerful than complete external validation.
| C ONC LUSI ON
This study validates the performance of the V-RESOLVE score system to predict the risk of SB occlusion with provisional strategy, and to assist in decision-making with the useful risk stratification of SB occlusion in coronary bifurcation intervention.
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